Evidence map›Paper›PMID 26085811›Full record

ArticleCurrent genomics2015

A Comparative Analysis and Review of lysyl Residues Affected by Posttranslational Modifications.

Luca Cesaro, Lorenzo A Pinna, Mauro Salvi

Open access · greenAbstract read
In one paragraph

Article in Current genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Gold-Based Pharmacophore Inhibits Intracellular MYC Protein.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021
    Article
  3. Article
  4. Article
  5. Non-degradative Ubiquitination of Protein Kinases.PLoS computational biology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Luca CesaroDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, Padova, Italy.
Lorenzo A PinnaDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, Padova, Italy ; Institute of Neurosciences, V.le G. Colombo 3, Padova, Italy.
Mauro SalviDepartment of Biomedical Sciences, University of Padova, Via U. Bassi 58/B, Padova, Italy.
University of Padua · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-translational modification is the most common mechanism of regulating protein function. If phosphorylation is considered a key event in many signal transduction pathways, other modifications must be considered as well. In particular the side chain of lysine residues is a target of different modifications; notably acetylation, methylation, ubiquitylation, sumoylation, neddylation, etc. Mass spectrometry approaches combining highly sensitive instruments and specific enrichment strategies have enabled the identification of modified sites on a large scale. Here we make a comparative analysis of the most representative lysine modifications (ubiquitylation, acetylation, sumoylation and methylation) identified in the human proteome. This review focuses on conserved amino acids, secondary structures preference, subcellular localization of modified proteins, and signaling pathways where these modifications are implicated. We discuss specific differences and similarities between these modifications, characteristics of the crosstalk among lysine post translational modifications, and single nucleotide polymorphisms that could influence lysine post-translational modifications in humans.

Indexed as

AcetylationLysine post-translational modificationsMethylationSignalingSumoylationUbiquitylation.

Identifiers

PMID26085811
PMCPMC4467303
OpenAlexW1980756912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.